| INTRODUCTION

Spontaneous bacterial peritonitis (SBP) is a common life-threatening
bacterial infection in patients with cirrhosis. [1] [2] [3] In-hospital mortality after the first episode of SBP ranges from 10% to 50%, and among those who survive, 70% will have a recurrent episode within 1 year. [4] [5] [6] Current guidelines recommend antimicrobial prophylaxis in patients with a high risk of developing SBP (i.e. Child-Turcotte-Pugh
[CTP] score ≥9 and bilirubin ≥3 mg/dL, or ascites fluid total protein <1.5 g/dL with impaired renal function defined as creatinine ≥1.2 mg/dL, blood urea nitrogen ≥25 mg/dL or serum sodium ≤130 mmol/L) and those with a prior episode of SBP. 7, 8 Unfortunately, even with stewarded use, there has been a notable increase in antibiotic-resistant infections. [9] [10] [11] First-line treatment of SBP with a third-generation cephalosporin has become less effective with resistance noted in 20% of patients in some studies. 12, 13 The high rates of antibiotic resistance result in failure to effectively treat this infection and correspond with increased 30-day mortality. 13 Historically, Escherichia coli, Klebsiella pneumoniae and Streptococcal pneumonia were the most common aetiologies of SBP. 7 Recently, the prevalence of Gram-positive bacteria including methicillin-resistant Staphylococcus aureus and enterococci isolated from patients with SBP has increased. 9, 13, 14 The development of extended-spectrum beta-lactamases and fluoroquinolone-resistant bacteria following norfloxacin prophylaxis have also reduced the efficacy of standard SBP prophylaxis. 9, 10 Prior studies have reported resistance to norfloxacin or trimethoprim/sulfamethoxazole in 30%-45% of bacterial isolates from ascites. 11, 13 This changing bacteriology landscape has led to the evaluation of alternative antibiotics for SBP prophylaxis.
Rifaximin is a non-absorbed, gut-selective antibiotic with a broad range of coverage and low resistance profile that is commonly used to treat hepatic encephalopathy in patients with cirrhosis. 15 Due to its high concentration in the enteric system, rifaximin has the potential advantage of preventing intestinal bacterial overgrowth and translocation without the systemic side effects of broad-spectrum antibiotics. 16, 17 Several studies evaluating the effectiveness of rifaximin in preventing SBP in high risk patients have shown inconsistent results. [18] [19] [20] [21] [22] [23] [24] [25] [26] We conducted a systematic review and meta-analysis to evaluate the efficacy of rifaximin in the prevention of SBP.
| MATERIALS AND METHODS
| Literature search
We performed a systematic literature search of five databases:
PubMed (includes MEDLINE), Scopus, the Cochrane Library, Google 
| Inclusion and exclusion criteria
All records identified through database searches were downloaded and duplicate records were removed. The title and abstract of remaining records were screened for relevance to liver disease and human subjects. After this initial screening, the lists of selected studies were cross-checked to resolve discrepancies. Subsequently, full articles were retrieved for detailed assessment.
Included studies met the following criteria: (1) 
| Quality assessment
The Newcastle-Ottawa Scale (NOS) was used to assess the quality of non-randomised studies included in this meta-analysis. The NOS measures quality in three domains: selection, comparability, and exposure. High-quality studies were considered to have a score of seven or greater, consistent with other meta-analyses. The
Cochrane Risk of Bias Tool for assessing risk of bias was used to assess the quality of randomised controlled trials. Study quality was assessed independently by two investigators (A.G. and U.R.), and any discrepancies were addressed by a joint evaluation of the original article.
| Statistical analysis
Rifaximin was compared with systemically absorbed antibiotics and no antibiotics in two separate analyses. The primary outcome of this study was the rate of SBP. We derived estimates of pooled odds ratio (OR) and 95% confidence interval (CI) for the outcome of interest using random-effect modelling. Heterogeneity was assessed using the Q and I 2 statistics and considered significant if P < .10 for
. 27 In addition, we utilised Egger's test to assess for publication bias. Sensitivity analysis was performed by excluding studies with significant clinical heterogeneity or studies of very poor quality. 28 Additional subgroup analysis was performed for primary and secondary SBP prophylaxis. Primary prophylaxis was defined as treatment for patients with no prior history of SBP at the time of study inclusion and secondary prophylaxis as therapy for patients with prior history of SBP. Authors of primary studies were contacted to obtain additional data for subgroup analysis when needed. All statistical analyses were conducted using Comprehensive Meta-Analysis, version 2 (Biostat, Englewood, NJ, USA).
3 | RESULTS
| Literature search
Our database search yielded 333 potential records for inclusion studies were included for full text review. Of those reviewed in detail, 63 were excluded because they were not original studies, 39 were excluded because they did not provide data related to rifaximin exposure, 15 were excluded because they did not report data on SBP outcomes and four were excluded due to inadequate clinical trial information. Overall, nine studies were included in the meta-analysis: three randomised trials and 6 cohort studies as detailed in Figure 1 .
18,20-26
| Study characteristics
Five studies compared rifaximin to systemic antibiotics 18, 19, 21, 22, 26 and five studies compared rifaximin to placebo 20, 21, [23] [24] [25] in the prevention of SBP. Lutz et al included patients in all three treatment groups (rifaximin, systemic antibiotics and placebo) and this study was included in both meta-analyses. 21 The majority of studies included decompensated patients with CTP class B or C only. Demographic information, presence of hepatic encephalopathy, rifaximin dose, duration of follow-up, among other features of the included studies are detailed in Table 1 . Detailed quality assessments of the included studies are provided in Tables S1 and S2 . Figure 2 ). There was significant heterogeneity among the five studies included in the analysis (Q = 9.44, degrees of freedom
[df] = 4, P = .05). According to the I 2 value, 58% of the variability in effect estimates was due to heterogeneity between the studies rather than a sampling error or chance.
Primary analysis was repeated after excluding the Lutz 2014 study as this study was of poor quality. This sensitivity analysis revealed that rifaximin was significantly more protective of SBP 
| Rifaximin compared to no antibiotics
Five candidate studies with a total of 784 patients were included in the analysis comparing rifaximin with no antibiotics for SBP prophylaxis; 186 (24%) patients received rifaximin and 598 (76%) patients were not on antibiotics. 20, 21, [23] [24] [25] Most patients had never experienced a prior episode of SBP although ascites total protein was low and 297 (38%) patients had a history of hepatic encephalopathy. The OR for the development of SBP was significantly lower in patients receiving rifaximin compared to no antibiotics at 0.34 (95% CI 0.11-0.99; P < .05) as shown in Figure 4 .
There was significant heterogeneity among the five studies included in the analysis (Q = 10.55, df = 4, P = .01). According to the I 2 value, 62% of the variability in effect estimates was due to heterogeneity between the studies rather than a sampling error or chance.
GOEL ET AL.
| 1031
Primary analysis was repeated after excluding the Lutz 2014 study again as this was a poor quality study. This sensitivity analysis revealed a strengthening of the finding that rifaximin was significantly more protective of SBP compared to no antibiotics (OR 0.21, 95% CI 0.09-0.45, P < .01) as shown in Figure 5 . Heterogeneity testing was repeated excluding the Lutz study and was no longer significant (Q = 0.50, df = 3, P = .92); I 2 value was 0%.
Subgroup analysis was performed based on the type of prophylaxis. Four studies 20-24 compared rifaximin to no antibiotics for primary SBP prophylaxis and only one study 21 
| DISCUSSION
In our systematic review and meta-analysis to assess the effectiveness of rifaximin in the prevention of SBP, we found that rifaximin is protective against the development of SBP compared to placebo and possibly compared to systemic antibiotics. To our knowledge, this is the first meta-analysis to report aggregate data from several studies evaluating the effectiveness of rifaximin in the prevention of SBP specifically.
Our findings support the theory that rifaximin may be beneficial in preventing SBP. This effect was significant when rifaximin was compared to no antibiotics with a 66% reduction in the risk of developing SBP in our pooled analysis cohort. When rifaximin was compared to systemic antibiotics, there was no clear benefit with To identify a particular group of patients that is more likely to benefit from rifaximin for SBP prophylaxis, subgroup analyses for primary and secondary prophylaxis was performed. In patients receiving primary prophylaxis, rifaximin significantly reduced the risk of SBP by 47% compared to no antibiotics but not definitively compared to systemic antibiotics. Unfortunately, the group of patients categorised as needing primary prophylaxis was heterogeneous in the studies as some only included patients at particularly high risk of SBP (i.e. CTP score >9 and bilirubin >3 mg/dL, ascites fluid total protein <1.5 g/dL, and impaired renal function defined as creatinine >1.2 mg/dL, blood urea nitrogen >25 mg/dL or serum sodium <130 mmol/L) and others included all cirrhotic patients with ascites. Upon removing the poor quality study, the risk reduction of SBP with rifaximin for primary prophylaxis was 77% compared to no antibiotics. In patients receiving secondary SBP prophylaxis, there was a 74% risk reduction with rifaximin compared to systemic antibiotics after removing the poor quality study. Likely due to ethical reasons and the current standard of care, there was only one study with data comparing rifaximin with no antibiotics for secondary SBP prophylaxis and hence a subgroup analysis could not be performed.
T A B L E 1 Characteristics of included studies
The shifting bacteriology of SBP and prevalence of antimicrobial resistance naturally raise the question of alternative prophylaxis strategies. The use of rifaximin to alter intestinal flora and the host immune system for the treatment of specific diseases is not novel.
Rifaximin has been studied and approved for the treatment of traveller's diarrhoea, small intestinal bacterial overgrowth and diarrhoea-predominant irritable bowel syndrome. 29 Compared with other systemically absorbed antibiotics for these indications, rifaximin decreases the risk of antibiotic resistance, has broad antimicrobial effects against Gram-positive and Gram-negative bacteria, and has a favourable safety and tolerability profile. 30 The strengths of our meta-analysis include an extensive database literature search in all languages and the inclusion of abstracts from relevant national conferences. The pooled patient population is geographically diverse with varied aetiologies of cirrhosis, which make the results more widely applicable. A majority of patients had CTP class B or C cirrhosis or MELD scores ≥15, which is representative of the population at greatest risk of developing SBP.
There are several limitations to our meta-analysis. First, while there were numerous studies evaluating rifaximin in liver disease, most only included results on hepatic encephalopathy and not SBP. Hence, there
were relatively few studies with data reporting the primary outcome of interest and only nine were included in the final meta-analysis. Second, the study designs varied from randomised controlled trials to observational cohort studies. Although most were of high quality, the inclusion criteria for patients varied with some studies only including those at highest risk of SBP 18, 19, 22, 26 and other studies evaluating all patients receiving a paracentesis, [20] [21] [22] [23] [24] the former enriching for events while the latter biasing towards the null. Third, we were unable to stratify outcomes based on the use of rifaximin for primary or secondary prophylaxis. The risk of developing an initial episode of SBP in a cirrhotic patient with ascites is 20% compared to a 70% risk of developing recurrent infection within 1-year. [4] [5] [6] This distinction is important as it likely represents two different patient populations that require separate studies. In our meta-analysis, three studies included patients that required either primary or secondary SBP prophylaxis, 21, 22, 25 two studies included only primary prophylaxis, 19, 20 two studies included only secondary prophylaxis, 18, 26 and two studies did not specify prior SBP history. 23, 24 Lastly, there was significant heterogeneity among the studies. To
Study name
Odds ratio evaluate the impact of each study on the overall pooled estimates, sensitivity was performed as noted in Figures 3 and 5 .
In summary, rifaximin may be effective for both primary and secondary SBP prophylaxis in patients with cirrhosis and ascites compared to systemically absorbed antibiotics and compared to no intervention. This is appealing but early data given the aforementioned evolving antimicrobial resistance profiles and the wide-ranging effects of gut dysbiosis as a consequence of systemic rather than localised antibiotic therapy. Additional prospective studies are required to confirm these findings for both primary and secondary prophylaxis before a change in clinical practice can be recommended.
The use of rifaximin for SBP prophylaxis would add to the already documented benefit of rifaximin in the treatment of hepatic encephalopathy in patients with liver disease, reduce antibiotic resistance, and allow for simplification of medication regimens in a complex patient population.
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